Johnson & Johnson Initiates P-I/IIa Study of its Ad26.COV2.S Against COVID-19 in the US and Belgium
Shots:
- J&J’s Ad26 vector-based vaccine demonstrated robust immune response in the pre-clinical study by neutralizing Abs- preventing infection and provide complete/ near-complete protection in the lungs from the virus in NHPs
- Based on the preclinical studies- the company has commenced the P-I/IIa study of Ad26.COV2.S- in healthy volunteers in the US and Belgium with expected initiation of P-III study in Sept’2020. The P-I/IIa study will evaluate the safety- reactogenicity- and immunogenicity of Ad26.COV2.S in ~1-000 healthy adults aged 18-55yrs. and 65+ yrs.
- Additionally- the company is planning to initiate P-III clinical trial program- will evaluate both one/two-dose regimens of Ad26.COV2.S initiate in parallel studies while the P-IIa study in the Netherlands- Spain- and Germany and a P-I study in Japan in underway
Ref: Johnson & Johnson | Image: StraitTimes
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com